Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / news releases / chugai in licenses at 527 rights from roche for covi

AVIR - Chugai in-licenses AT-527 rights from Roche for COVID-19 in Japan

Atea Pharmaceuticals Inc.
Chugai Pharmaceutical (CHGCF) has in-licensed the rights for Atea Pharmaceuticals' (AVIR) AT-527 for the treatment of COVID-19 in Japan from Roche (RHHBY).Roche and Atea are jointly developing AT-527 for COVID-19 and Roche has the right to commercialize AT-527 outside U.S. The companies collaborated in October 2020 to accelerate the development and manufacturing of AT-527.Atea made a U.S. debut in October 2020. The company is currently trading 247.5% higher at around $83.40, above IPO price of $24.

For further details see:

Chugai in-licenses AT-527 rights from Roche for COVID-19 in Japan
Stock Information
Company Name: Atea Pharmaceuticals Inc.
Stock Symbol: AVIR
Market: NASDAQ
Website: ateapharma.com
Menu
AVIR AVIR Quote AVIR Short AVIR News AVIR Articles AVIR Message Board
Get AVIR Alerts

News, Short Squeeze, Breakout and More Instantly...